What are Protease inhibitor combination drugs?

Protease inhibitor combination drugs are pharmacologic agents that share a common mechanism (typically targeting HIV protease). 2 are currently marketed, with 2 more in clinical development.

What are the marketed Protease inhibitor combination drugs?

Marketed Protease inhibitor combination drugs include Lopinavir/ritonavir simplification strategy, Kaletra + Current Dual NRTI Backbone.

Protease inhibitor combination

2 marketed 2 in Phase 3

This page covers all Protease inhibitor combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HIV protease.

Targets

HIV protease

Marketed (2)

Lopinavir/ritonavir simplification strategy · Fundación Huésped · Infectious Disease
A treatment strategy that simplifies HIV management by optimizing the dosing or administration of lopinavir/ritonavir, a protease inhibitor combination, to improve adherence and reduce pill burden.
Kaletra + Current Dual NRTI Backbone · University of Chicago · Infectious Disease
Kaletra is a protease inhibitor combination that blocks HIV protease to prevent viral replication, used as part of a three-drug antiretroviral regimen with two nucleoside reverse transcriptase inhibitors.

Phase 3 pipeline (2)

Protease Inhibitor/ritonavir · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Infectious Disease
This combination inhibits HIV protease while ritonavir acts as a pharmacokinetic booster to increase protease inhibitor levels in the bloodstream.
Lopinavir-ritonavir (LPV-RTV) · National Institute of Allergy and Infectious Diseases (NIAID) · Infectious Disease
Lopinavir-ritonavir is a combination of two protease inhibitors that block HIV protease, preventing the cleavage of viral polyproteins and stopping HIV replication.